A Single-blind, Randomized, Placebo-controlled, Phase 1, Single Ascending-dose and Repeat-dose, Safety and Tolerability Study of Intravenous AVB-S6-500 in Healthy Subjects
Latest Information Update: 23 May 2022
At a glance
- Drugs Batiraxcept (Primary)
- Indications Acute myeloid leukaemia; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Aravive Biologics
- 13 Apr 2022 Data from NCT03401528 and NCT03639246 were used to develop a PK PD model presented at the 113th Annual Meeting of the American Association for Cancer Research
- 16 Nov 2018 Results presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- 13 Nov 2018 Results presented in an Aravive Media Release.